Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy

被引:652
|
作者
O'Hanlon, Rory [1 ]
Grasso, Agata [1 ]
Roughton, Michael
Moon, James C. [4 ]
Clark, Susan [1 ]
Wage, Ricardo [1 ]
Webb, Jessica [1 ]
Kulkarni, Meghana [1 ]
Dawson, Dana [1 ]
Sulaibeekh, Leena [1 ]
Chandrasekaran, Badri [1 ]
Bucciarelli-Ducci, Chiara [1 ]
Pasquale, Ferdinando [4 ]
Cowie, Martin R. [2 ]
McKenna, William J. [5 ]
Sheppard, Mary N. [3 ]
Elliott, Perry M. [5 ]
Pennell, Dudley J. [1 ]
Prasad, Sanjay K. [1 ]
机构
[1] Royal Brompton & Harefield NHS Fdn Trust, Dept Cardiovasc Magnet Resonance, London, England
[2] Royal Brompton & Harefield NHS Fdn, Dept Cardiovasc Med, London, England
[3] Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England
[4] UCL, Dept Cardiovasc Magnet Resonance, London WC1E 6BT, England
[5] UCL, Dept Cardiovasc Med, London WC1E 6BT, England
基金
美国国家卫生研究院;
关键词
cardiovascular magnetic resonance; hypertrophic cardiomyopathy; late gadolinium enhancement; myocardial fibrosis; CARDIOVASCULAR MAGNETIC-RESONANCE; LATE GADOLINIUM ENHANCEMENT; DELAYED ENHANCEMENT; CLINICAL PROFILE; PREVALENCE; HEART;
D O I
10.1016/j.jacc.2010.05.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We investigated the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic resonance for the prediction of major clinical events in hypertrophic cardiomyopathy (HCM). Background The role of myocardial fibrosis in the prediction of sudden death and heart failure in HCM is unclear with a lack of prospective data. Methods We assessed the presence and amount of myocardial fibrosis in HCM patients and prospectively followed them for the development of morbidity and mortality in patients over 3.1 +/- 1.7 years. Results Of 217 consecutive HCM patients, 136 (63%) showed fibrosis. Thirty-four of the 136 patients (25%) in the fibrosis group but only 6 of 81 (7.4%) patients without fibrosis reached the combined primary end point of cardiovascular death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrillation, or appropriate implantable cardioverter-defibrillator discharge (hazard ratio [HR]: 3.4, p = 0.006). In the fibrosis group, overall risk increased with the extent of fibrosis (HR: 1.18/5% increase, p = 0.008). The risk of unplanned heart failure admissions, deterioration to New York Heart Association functional class III or IV, or heart failure-related death was greater in the fibrosis group (HR: 2.5, p = 0.021), and this risk increased as the extent of fibrosis increased (HR: 1.16/5% increase, p = 0.017). All relationships remained significant after multivariate analysis. The extent of fibrosis and nonsustained ventricular tachycardia were univariate predictors for arrhythmic end points (sustained ventricular tachycardia or ventricular fibrillation, appropriate implantable cardioverter-defibrillator discharge, sudden cardiac death) (HR: 1.30, p = 0.014). Nonsustained ventricular tachycardia remained an independent predictor of arrhythmic end points after multivariate analysis, but the extent of fibrosis did not. Conclusions In patients with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic resonance is an independent predictor of adverse outcome. (The Prognostic Significance of Fibrosis Detection in Cardiomyopathy; NCT00930735) (J Am Coll Cardiol 2010;56:867-74) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:867 / 874
页数:8
相关论文
共 50 条
  • [1] Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy
    Hanlon, R. O'
    Grasso, A.
    Roughton, M.
    Moon, J. C.
    Wage, W.
    Bucciarelli-Ducci, C.
    Mckenna, W. J.
    Elliott, P. M.
    Pennell, D. J.
    Prasad, S. K.
    EUROPEAN HEART JOURNAL, 2010, 31 : 331 - 331
  • [2] Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance
    O'Hanlon R.
    Grasso A.
    Roughton M.
    Moon J.C.
    Clarke S.
    Wage R.
    Webb J.
    Kulkarni M.
    Dawson D.
    Sulaibeekh L.
    Chandrasekaran B.
    Bucciarelli-Ducci C.
    Pasquale F.
    Cowie M.R.
    McKenna W.J.
    Burke M.
    Sheppard M.
    Elliot P.M.
    Pennell D.J.
    Prasad S.K.
    Journal of Cardiovascular Magnetic Resonance, 12 (Suppl 1)
  • [3] Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study
    Zhu, Antonia
    Bews, Hilary
    Cheung, David
    Nagalingam, Raghu S.
    Mittal, Ishika
    Goyal, Vineet
    Asselin, Chantal Y.
    Kirkpatrick, Iain D. C.
    Czubryt, Michael P.
    Jassal, Davinder S.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2020, 98 (07) : 459 - 465
  • [4] Progression of myocardial fibrosis in hypertrophic cardiomyopathy
    Aquaro, Giovanni Donato
    Todiere, Giancarlo
    Barison, Andrea
    HEART, 2015, 101 (19) : 1602 - 1602
  • [5] Myocardial Fibrosis in Hypertrophic Cardiomyopathy REPLY
    Ho, Carolyn Y.
    Seidman, Christine E.
    Diez, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1971 - 1971
  • [6] Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
    Nakamori, Shiro
    Rowin, Ethan J.
    Jaafar, Narjes
    Rodriguez, Jennifer
    Ngo, Long H.
    Manning, Warren J.
    Maron, Martin
    Nezafat, Reza
    CIRCULATION, 2023, 148
  • [7] Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
    Habib, Manhal
    Adler, Arnon
    Fard, Kimia
    Hoss, Sara
    Hanneman, Kate
    Rowin, Ethan J.
    Maron, Martin S.
    Maron, Barry J.
    Rakowski, Harry
    Chan, Raymond H.
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (05) : 947 - 958
  • [8] Correlates of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
    Kramer, Christopher M.
    Appelbaum, Evan
    Desai, Milind Y.
    Desvigne-Nickens, Patrice
    DiMarco, John P.
    Dolman, Sarahfaye
    Friedrich, Matthias F.
    Geller, Nancy
    Ho, Carolyn Y.
    Jerosch-Herold, Michael
    Kim, Dong-Yun
    Kolm, Paul
    Kwong, Raymond Y.
    Maron, Martin S.
    Schulz-Menger, Jeanette
    Piechnik, Stefan
    Watkins, Hugh
    Weintraub, William S.
    Neubauer, Stefan
    CIRCULATION, 2018, 138
  • [9] Quantification and Significance of Diffuse Myocardial Fibrosis and Diastolic Dysfunction in Childhood Hypertrophic Cardiomyopathy
    Tarique Hussain
    Andreea Dragulescu
    Lee Benson
    Shi-Joon Yoo
    Howard Meng
    Jonathan Windram
    Derek Wong
    Andreas Greiser
    Mark Friedberg
    Luc Mertens
    Michael Seed
    Andrew Redington
    Lars Grosse-Wortmann
    Pediatric Cardiology, 2015, 36 : 970 - 978
  • [10] CLINICAL SIGNIFICANCE OF DIFFERENT ASSESMENT METHODS OF MYOCARDIAL FIBROSIS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
    Zaitsev, V. V.
    Gurshchenkov, A., V
    Mitrofanova, L. B.
    Ryzhkov, A., V
    Kazakova, E. E.
    Badaev, K. D.
    Gordeev, M. L.
    Moiseeva, O. M.
    KARDIOLOGIYA, 2020, 60 (03) : 44 - 50